Literature DB >> 2872797

Hormonal risk factors in testicular cancer. A case-control study.

A R Moss, D Osmond, P Bacchetti, F M Torti, V Gurgin.   

Abstract

The authors interviewed 273 northern California testicular cancer cases aged 40 and under diagnosed between 1976 and 1981, their mothers, and matched peer controls and their mothers on prenatal hormone exposure and other variables. Included was a population-based substudy (1979-1981) of all interviewable cases reported to the San Francisco Bay Area Surveillance, Epidemiology, and End Results registry. They found odds ratios (OR) of from 8.3 (sons' report) to 4.5 (mothers' report) associated with cryptorchidism, but found no association with mothers' hormone exposure or diethylstilbestrol exposure in pregnancy. They also found a significant association with lower age at puberty (OR = 2.0); a marginally significant association with mothers' breast cancer (OR = 2.9, p = 0.054); and a significant protective effect of reported mononucleosis (OR = 0.6). These associations remained strong in the population-based substudy. When cases were divided by histology, strong and specific associations of earlier puberty (OR = 2.3) and mothers' breast cancer (OR = 4.4) with nonseminomatous cancer, and of reported mononucleosis (OR = 0.3) with seminomatous cancer, were found. These observations suggest that 1) prenatal exogenous hormone exposure does not account for a significant fraction of testicular cancer, 2) a cluster of "breast-cancer-like" risk factors are associated with nonseminomas, and 3) there is some genetic risk of nonseminomas.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872797     DOI: 10.1093/oxfordjournals.aje.a114369

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  49 in total

Review 1.  Clinical epidemiology of testicular germ cell tumors.

Authors:  K-P Dieckmann; U Pichlmeier
Journal:  World J Urol       Date:  2004-03-18       Impact factor: 4.226

Review 2.  A systematic review and meta-analysis of perinatal variables in relation to the risk of testicular cancer--experiences of the son.

Authors:  Michael B Cook; Olof Akre; David Forman; M Patricia Madigan; Lorenzo Richiardi; Katherine A McGlynn
Journal:  Int J Epidemiol       Date:  2010-07-26       Impact factor: 7.196

3.  Does vasectomy accelerate testicular tumour? Importance of testicular examinations before and after vasectomy.

Authors:  A R Cale; M Farouk; R J Prescott; I W Wallace
Journal:  BMJ       Date:  1990-02-10

4.  Vasectomy and testicular cancer.

Authors:  R R West
Journal:  BMJ       Date:  1992-03-21

5.  Incidence at birth and natural history of cryptorchidism: a study of 10,730 consecutive male infants.

Authors:  P Ghirri; C Ciulli; M Vuerich; A Cuttano; M Faraoni; L Guerrini; C Spinelli; S Tognetti; A Boldrini
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

6.  Incidence of disease after vasectomy: a record linkage retrospective cohort study.

Authors:  H Nienhuis; M Goldacre; V Seagroatt; L Gill; M Vessey
Journal:  BMJ       Date:  1992-03-21

Review 7.  A systematic review and meta-analysis of perinatal variables in relation to the risk of testicular cancer--experiences of the mother.

Authors:  Michael B Cook; Olof Akre; David Forman; M Patricia Madigan; Lorenzo Richiardi; Katherine A McGlynn
Journal:  Int J Epidemiol       Date:  2009-09-23       Impact factor: 7.196

Review 8.  Why is the rate of testicular cancer increasing?

Authors:  L H Klotz
Journal:  CMAJ       Date:  1999-01-26       Impact factor: 8.262

9.  An exploratory analysis of risk factors for childhood malignant germ-cell tumors: report from the Childrens Cancer Group (Canada, United States).

Authors:  X O Shu; M E Nesbit; J D Buckley; M D Krailo; L L Robinson
Journal:  Cancer Causes Control       Date:  1995-05       Impact factor: 2.506

Review 10.  Etiologic factors in testicular germ-cell tumors.

Authors:  Katherine A McGlynn; Michael B Cook
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.